Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 12/20 | 0.88 |
| ▸ | CYP2C9 | P11712 | 10/20 | 0.88 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.85 |
| ▸ | BRAF | P15056 | 2/20 | 0.85 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.85 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.85 |
| ▸ | EGFR | P00533 | 1/20 | 0.85 |
| ▸ | KRAS | P01116 | 1/20 | 0.85 |
| ▸ | RAF1 | P04049 | 1/20 | 0.85 |
| ▸ | PGR | P06401 | 1/20 | 0.85 |
| ▸ | RET | P07949 | 1/20 | 0.85 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.85 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.85 |
| ▸ | ARAF | P10398 | 1/20 | 0.85 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.85 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.85 |
| ▸ | FECH | P22830 | 1/20 | 0.85 |
| ▸ | KDR | P35968 | 1/20 | 0.85 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.85 |
| ▸ | TGFBR2 | P37173 | 1/20 | 0.85 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL295650 | 0.93 | CYP2C19 (1.00) | CYP2C19CYP2C9CYP3A4BRAFRIPK2 | |
| SCHEMBL299611 | 0.93 | CYP2C19 (0.86) | CYP2C19CYP2C9CYP3A4BRAFRIPK2 | |
| SCHEMBL29898551 | 0.93 | CYP2C19 (0.86) | CYP2C19CYP2C9CYP3A4BRAFRIPK2 | |
| SCHEMBL298927 | 0.93 | BRAF (0.89) | CYP2C19CYP2C9CYP3A4BRAFRIPK2 | |
| SCHEMBL298257 | 0.92 | CYP2C19 (1.00) | CYP2C19CYP2C9CYP3A4BRAFRIPK2 | |
| SCHEMBL27103816 | 0.92 | CYP2C19 (0.85) | CYP2C19CYP2C9CYP3A4BRAFRIPK2 | |
| SCHEMBL855840 | 0.92 | BRAF (0.87) | CYP2C19CYP2C9CYP3A4BRAFRIPK2 | |
| SCHEMBL298373 | 0.92 | BRAF (0.87) | CYP2C19CYP2C9CYP3A4BRAFRIPK2 | |
| SCHEMBL29898578 | 0.92 | BRAF (0.87) | CYP2C19CYP2C9CYP3A4BRAFRIPK2 | |
| SCHEMBL12891936 | 0.92 | BRAF (1.00) | CYP2C19CYP2C9CYP3A4BRAFRIPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120245174-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2012-09-27 | — | — | US | disclosed |
| US-20120245174-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2012-09-27 | — | — | US | disclosed |
| US-8198273-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2012-06-12 | — | — | US | disclosed |
| US-8198273-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2012-06-12 | — | — | US | disclosed |
| US-20120122860-A1 | SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS | PLEXXIKON, INC. | 2012-05-17 | — | — | US | disclosed |
| US-20120122860-A1 | SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS | PLEXXIKON, INC. | 2012-05-17 | — | — | US | disclosed |
| WO-2010129570-A1 | SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS | PLEXXIKON, INC. (US) | 2010-11-11 | — | — | WO | disclosed |
| US-20100286142-A1 | Compounds and Methods for Kinase Modulation, and Indications Therefor | PLEXXIKON, INC. | 2010-11-11 | — | — | US | disclosed |
| US-20100286142-A1 | Compounds and Methods for Kinase Modulation, and Indications Therefor | PLEXXIKON, INC. | 2010-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122860-A1 | SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS | BRAF, RAF1, ARAF | CYP2C19 2730/4885CYP2C9 2176/4885CYP3A4 3611/4885 |
| US-20100286142-A1 | Compounds and Methods for Kinase Modulation, and Indications Therefor | BRAF, ARAF, RAF1 | CYP2C19 2678/4885CYP2C9 2237/4885CYP3A4 2892/4885 |
| US-20120245174-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | BRAF, ARAF, RAF1 | CYP2C19 2678/4885CYP2C9 2237/4885CYP3A4 2892/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.